Exelixis (NASDAQ:EXEL) Sets New 52-Week High Following Analyst Upgrade

Posted by Stanley Muller on Jul 2nd, 2026

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after UBS Group raised their price target on the stock from $43.00 to $52.00. UBS Group currently has a neutral rating on the stock. Exelixis traded as high as $56.11 and last traded at $55.9670, with a volume of 362658 shares changing hands. The stock had previously closed at $53.96.

EXEL has been the topic of several other reports. Truist Financial lowered Exelixis from a “buy” rating to a “hold” rating and upped their price target for the company from $51.00 to $54.00 in a research report on Thursday, June 25th. Wells Fargo & Company lifted their target price on Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Zacks Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Barclays raised their price target on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a report on Monday, April 20th. Finally, Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Nine equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $47.60.

View Our Latest Research Report on EXEL

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Exelixis

Several institutional investors and hedge funds have recently modified their holdings of EXEL. Anchor Investment Management LLC lifted its position in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after buying an additional 500 shares during the last quarter. Motiv8 Investments LLC acquired a new position in Exelixis during the fourth quarter valued at approximately $26,000. Cassaday & Co Wealth Management LLC acquired a new position in Exelixis during the first quarter valued at approximately $27,000. Western Wealth Management LLC bought a new position in shares of Exelixis in the first quarter valued at approximately $29,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in shares of Exelixis in the fourth quarter worth $29,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 3.0%

The company’s fifty day moving average is $50.18 and its 200-day moving average is $45.80. The firm has a market capitalization of $13.98 billion, a P/E ratio of 18.47, a P/E/G ratio of 1.57 and a beta of 0.42.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 EPS. On average, equities research analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current year.

About Exelixis

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.